Researchers identify a novel approach to enhance tissue growth
STUDY FINDINGS OFFER PROMISING NEW DIRECTION FOR ORGAN REGENERATION AND TISSUE REPAIR
Because most human tissues do not regenerate spontaneously, advances in tissue repair and organ regeneration could benefit many patients with a wide variety of medical conditions.
Now a research team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center has identified an entirely new approach to enhance normal tissue growth, a finding that could have widespread therapeutic applications.
Their findings were published on-line this week in the Proceedings of the National Academy of Sciences (PNAS).
Tissue regeneration is a process that is not fully understood, but previous research has demonstrated that endothelial cells lining the insides of small blood vessels play a key role in tissue growth. It is also known that these endothelial cells generate chemical messengers called epoxyeicosatrienoic acids (EETs), which stimulate blood vessel formation in response to tissue injury.
In this new research, first author Dipak Panigrahy, MD, an investigator in BIDMC’s Center for Vascular Biology Research, and his colleagues wanted to find out how EETs might participate in organ and tissue regeneration. To answer this question, they created seven different mouse models. The models focused on liver, kidney and lung regeneration; wound healing; corneal vascularization; and retinal vascularization.
“We used genetic and pharmacologic tools to manipulate EET levels in the animals to show that EETs play a critical role in accelerating tissue growth, providing the first in vivo demonstration that pharmacological modulation of EETs can affect organ regeneration,” explains Panigrahy, an Instructor in Pathology at Harvard Medical School. Administering synthetic EETs spurred tissue growth in the research models; conversely, lowering EET levels – by either manipulating genes or administering drugs – delayed tissue regeneration.
The team also demonstrated that proteins called soluble epoxide hydrolase (sEH) inhibitors, known to elevate EET levels, promoted liver and lung regeneration. (sEH is the main metabolizing enzyme of EETs.)
“Our results offer a mechanistic rationale for evaluating sEH inhibitors as novel therapeutics for a number of human diseases such as hepatic insufficiency after liver damage and diseases characterized by immature lung development, such as bronchopulmonary dysplasia,” says Panigrahy, adding that the use of topical sEH inhibitors on the skin might also be useful for the acceleration of wound healing.
The researchers suspected that EETs were stimulating tissue regeneration by way of blood vessel formation, specifically by producing vascular endothelial growth factor (VEGF) to promote vessel growth. As predicted, when the investigators depleted VEGF in the mice, EETs’ effects on organ regeneration disappeared.
“Discovering EETs’ role could be of critical importance to help control the repair of liver, lungs and kidneys,” says senior author Mark Kieran, MD, PhD, of the Division of Pediatric Oncology at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. “Since diseases of these organs are a major cause of morbidity and mortality in the North American population, the opportunity to modulate the regeneration of healthy tissue could have significant therapeutic implications for many patients.” These findings may also apply to conditions or physical defects that lead to the loss of specialized cells in other organ systems, such as the nervous system and the immune system.
The Latest on: Organ Regeneration
- Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosison January 2, 2020 at 7:37 pm
Therapeutic strategies inhibiting YAP and TAZ have been hindered by the critical role that these proteins play in regeneration and homeostasis in different cell types. Here, we find that the Gα ...
- Tissue Regeneration Market 2019 Industry Outlook, Comprehensive Insights, Growth and Forecast 2025 – Market Research Engineon December 26, 2019 at 4:14 am
New York, December 26, 2019: The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled ...
- Tissue Regeneration and Organ Repair: Science or Science Fiction?on December 21, 2019 at 4:00 pm
The demand for tissue and organ replacement following tissue damage (eg, severe burns) or diseases (eg, cardiomyopathy) is expanding, and, while the number of patients suffering from organ failure is ...
- UAB bioprinter shows potential to accelerate tissue engineeringon December 6, 2019 at 5:28 am
The dream of tissue engineering is a computer-controlled manufacturing of complex and functional human tissue for potential organ regeneration or replacement. University of Alabama at Birmingham ...
- With cellular blueprint for lungs, researchers look ahead to organ regenerationon December 5, 2019 at 6:07 am
"We can take an entire organ, or tissue, and measure all the cell types from ... Bioengineered lungs in various stages of regeneration in Niklason's lab are developing inside custom-designed glass ...
- Researchers create lung 'blueprint' that could aid organ regenerationon December 5, 2019 at 5:13 am
This is a complicated procedure that has other adverse health effects and oftentimes simply doesn't work, so for scientists in this field, organ regeneration -- that is, growing an organ from the body ...
- Fighting cancer: How growing mini organs could create better treatmenton December 2, 2019 at 5:25 am
Stem cell technology lets us grow mini organs from scratch, providing new opportunities to develop personalised cancer treatments. Vivian Li explains how body regeneration is becoming more than sci-fi ...
- Special cells contribute to regenerate the heart in zebrafishon October 24, 2019 at 3:52 am
The insights gained could be used to initiate a similar repair process in the human heart. Zebrafish are extremely well-suited for the study of organ regeneration. After heart injury, zebrafish ...
- LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of its Liver Regeneration Technologyon October 21, 2019 at 5:37 am
PITTSBURGH, Oct. 21, 2019 /PRNewswire/ -- LyGenesis, Inc., a biotechnology company focused on organ regeneration, announced today that they have completed a total of $4 million in private financing of ...
via Google News and Bing News